SREBF1 and fatty liver disease: While mTORC1 pathway has been shown to induce SREBP-1c and promote hepatic lipogenesis5, 9, activation of AMPK pathway e.g., by the antidiabetic drug metformin and thiazolidinediones, accounts for its therapeutic effects on liver steatosis through inhibition of SREBP-1c7, 10, 11.